ArticleScientific reports2025
ANTP-SmacN7 enhances radiosensitivity in TPC-1 cells through XIAP-mediated activation of apoptotic protein.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A subset of differentiated thyroid cancer still lacks effective treatment options, such as locally advanced or metastatic patients. Some of these patients also need to try radiation therapy. The objective of this study is to investigate the potential of the antennapedia-modified SMAC fragment (ANTP-SmacN7) as a radiation sensitizer to enhance the therapeutic efficacy of radiotherapy in papillary carcinoma of thyroid (PTC), ascertain the contribution of X-linked inhibitor of apoptosis protein (XIAP), and explore its associated mechanisms to the apoptotic response in PTC. Methods To determine whether ANTP-SmacN7 enhances radiotherapy sensitivity by promoting apoptosis through XIAP in thyroid cancer, we first performed bioinformatics analysis of XIAP in thyroid cancer (THCA) using TCGA/GTEx THCA datasets. This analysis evaluated XIAP expression levels, its correlation with clinical pathological features and prognosis, functional enrichment, and interactions with apoptosis-related genes of CASP. Subsequently, we treated TPC-1 cells with gamma ray and ANTP-SmacN7 in different groups and assessed cell proliferation, migration, and apoptosis-related protein expression (XIAP, caspase-3, caspase-8, and caspase-9) using CCK-8, colony formation, transwell assays, annexin V/PI double staining, and western blotting. To further elucidate the role of XIAP and the effects of ANTP-SmacN7, we constructed XIAP-overexpressing TPC-1 cells, treated them with gamma ray and ANTP-SmacN7 in different groups, and compared changes of cell function and apoptosis-related protein. XIAP is highly expressed in THCA and demonstrates significant correlations with aggressive clinicopathological features including advanced T stage (p = 0.018) and extrathyroidal extension (p = 0.017) in THCA, while its prognostic stratification potential is evidenced by an AUC of 0.63. It interacts closely with CASP family members involved in apoptosis, which might critically inform therapeutic strategies for radioresistant THCA. The experimental results demonstrate that TPC-1 cells are sensitive to low-dose gamma ray but exhibit radioresistant as the radiation dose increases. While ANTP-SmacN7 significantly enhances gamma ray-induced radiosensitization. When combined with gamma ray, ANTP-SmacN7 markedly reduces cell proliferation, viability, and migration, while simultaneously promoting apoptosis. This effect is mediated by XIAP inhibition, which activates the intrinsic apoptosis pathway through caspase-3 and caspase-9. Additionally, XIAP influences the extrinsic apoptosis pathway by directly or indirectly upregulating caspase-8. ANTP-SmacN7 could be a probable candidate for a pharmaceutical radiosensitizer when combined with gamma ray for the treatment of PTC. These findings may provide a theoretical basis for the development of radiosensitization strategies for locally advanced or metastatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.